Liposomal Glutathione is a pharmaceutical-grade active ingredient in which reduced glutathione (GSH) — a tripeptide comprising cysteine, glycine, and glutamic acid, and the most concentrated endogenous antioxidant in the human body — is encapsulated within a phospholipid bilayer delivery system. This advanced formulation strategy directly resolves the fundamental limitation of conventional glutathione supplementation: rapid oxidative degradation of the active sulfhydryl group (–SH) before it can reach the bloodstream.
When taken orally without encapsulation, glutathione is systematically broken down by gastric acid and digestive enzymes into its component amino acids, resulting in negligible intracellular GSH elevation. The liposomal carrier overcomes this barrier by shielding the intact reduced glutathione molecule throughout the gastrointestinal transit and releasing it directly into cells via membrane fusion — an approach structurally analogous to the body's own vesicular transport mechanisms.
The phospholipid coat — typically comprising phosphatidylcholine and phosphatidylethanolamine in high-purity ratios — mimics the composition of biological cell membranes, allowing the liposome to fuse seamlessly with epithelial surfaces and deliver its payload intracellularly. The final product presents as an off-white, dry free-flowing powder with excellent aqueous dispersibility and a confirmed encapsulation efficiency exceeding 80%.
Beyond its role as an antioxidant, reduced glutathione plays essential biochemical roles in immune modulation, hepatic detoxification, melanin regulation, and mitochondrial protection — making its liposomal delivery format especially valuable for formulations targeting oxidative stress, ageing, skin health, immune resilience, and liver function.